ARCHIVES

FDA Designates Zometa For Priority Review.

This article is from The Cancer Letter archive.

Vol. 27 No. 44 | November 30, 2001

Download PDF Visit The Full Archive

Related Articles

Carfilzomib Demonstrates Clinical Benefit Rate of 64%

December 30, 2011

Zytiga and Prednisone Extends Overall Survival in mCRPC Trial

October 31, 2014

NCI Initiatives: Advisors Approves AIDS, Minority Training Programs

December 13, 1996

Surgical Oncology Status A Disaster, DCT board Told; Kramer Describes Radiotherapy Needs

April 20, 1979

Cancer Policy: Board Advocates $2 Per Pack Raise For Cigarettes

January 16, 1998

Tobacco Company Liggett Gave $3.6 Million To Henschke For CT Screening Research.

March 28, 2008